Dynavax Technologies and Berna Biotech Announce Collaboration

06-Nov-2003
Dynavax Technologies Corporation and Berna Biotech Ltd. today announced execution of a license and supply agreement under which Berna has granted Dynavax a worldwide, non-exclusive right to utilize Berna's hepatitis B surface antigen, HBsAg, in Dynavax's programs for the development of hepatitis B prophylactic vaccine and hepatitis B therapeutic products employing Dynavax's immunostimulatory sequence, or ISS, technology. Under the agreement, Berna will supply HBsAg to Dynavax and will have the right to elect to commercialize resulting vaccine and therapeutic products on an exclusive basis. Berna uses the proprietary Hansenula polymorpha yeast Expression System for the production of HBsAg antigen. This is the active ingredient of Berna's hepatitis B vaccine. More than 300 million doses of this vaccine have been supplied worldwide since 1996. No financial details were disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances